We are a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets.Through our wholly owned subsidiary, SkinJect, Inc. ("SkinJect"), we focus on
the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers. Prior to the Company's acquisition of SkinJect, our business was undertaken by SkinJect as a
stand-alone entity.
Lead Underwriter
Brookline Capital Markets, a division of Arcadia Securities, LLC,Maxim Group, LLC